Stifel Maintains Hold on RxSight, Lowers Price Target to $7
Stifel analyst Tom Stephan maintains RxSight (NASDAQ:RXST) with a Hold and lowers the price target from $8 to $7.
Read original at benzingaStocks · News reference
RxSight Appoints Aziz Mottiwala President, CEO, Effective July 20, Succeeding Ron Kurtz
RxSight, Inc. (NASDAQ:RXST) today announced a planned leadership transition effective July 20, 2026, with Aziz Mottiwala appointed President and Chief Executive Officer, succeeding Ron Kurtz, M.D., who will continue to
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 15, 2026, 8:16 PM
- Checked
- Jul 15, 2026, 8:16 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
UBS Maintains Neutral on RxSight, Raises Price Target to $6.3
UBS analyst Patrick Wood maintains RxSight (NASDAQ:RXST) with a Neutral and raises the price target from $5.5 to $6.3.
Read original at benzingaRxSight Q2 Adj. EPS $(0.11) Beats $(0.33) Estimate, Sales $33.741M Beat $32.547M Estimate
Read original at benzinga8-K filing — RxSight, Inc. (RXST)
Filed: 2026-07-15 AccNo: 0001193125-26-304812 Size: 186 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgar